Evaluation Of Serum 1,5 - Anhydroglucitol Levels among Type 2 Diabetic Patients in Basrah


  • Salman K.Ajlan MBChB, MSc, MRCP (Endocrinology & Diabetes, UK
  • Safa K.Qasim B.Sc


Diabetes mellitus, 1,5-AG level, glycaemic control


Objective: To determine serum 1,5- anhydroglucitol   (1,5-AG)   levels  among   patients  with type 2 diabetes (T2D) in Basrah, and to evaluate  the changes in 1,5-AG levels with regard to the status of glycaemic control. Methods: The present study included 76 patients with T2D, 33 males and 43 females, 30-78 years of age. Height, weight, waist circumference , systolic blood pressure, and diastolic blood pressure were  measured. Fasting blood glucose (FBG), glycated haemoglobin (HbA1c) and  serum 1,5-AG levels were determined. Results: The study revealed that T2D patients have low serum  1,5-AG concentrations (3.62 ±1.56) µg/ml. The comparative  male and female values were (3.69±1.55) µg/ml and (3.57±1.58) µg/ml.  The vast majority of the included diabetic patients (90.8%) were in a state  of poor glycemic control, with 6.6%   have an sub-optimal  metabolic control. On the other hand,  good  glycemic was documented in 2.6 % of patients. There were no significant differences in plasma 1,5-AG concentrations   with regard to the status of glycaemic control  (P > 0.05). Conclusion: T2D patients have reduced  serum 1,5-AG concentrations. Thus, it could be, potentially, valuable test for the diagnosis of diabetes mellitus. Diabetic patients were in poor glycaemic state. Therefore, they are at a substantial   risk for the development of  diverse  diabetic  complications.


Amos A, McCarry D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010.Diabetic Medicine 1987; 14: S1-S85.

King H, Aubert R, HermanW. Global Burden of Diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.

Kaveeshwar S, Cornwall J. The current state of diabetes mellitus in india. Australasian Medical Journal 2014; 7: 45-48.

Koga M, MuraiJ, Saito H, Mukai M, Kasayama S, et al. Habitual intake of dairy products influences serum 1,5- anhydroglucitol levels independently of plasma glucose. Diabetes Research and Clinical Practice 2010; 90: 122-125.

Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM, et al. Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabetic Medicine 1999; 16: 496-499.

Januszewski AS, Karschimku C, Davis KER, O,Neal D, Ward G, Jenkins AJ, et al. Plasma 1,5-anhydroglucitol levels, a measure of short term glycaemia: Assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Research and Clinical Practice 2012; 95: e17-e19.

Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, et al. Comparison of 1,5-anhydroglucitol, HbA1c, and Fructosamine for Detection of Diabetes Mellitus. Diabetes 1991; 40: 52-57.

Dworacka M, Wender-Ozegowska E, Winiarska H ,Borowska M, Zawiejska A, Pietryga M, et al. Plasma anhydro-D-glucitol (1,5-AG ) as an indicator of hyperglycaemia excursions in pregnant women with diabetes. Diabetic Medicine 2006; 23: 171-175.

Won JC, Park CY, Park HS, et al. 1,5-anhydro-D-glucitolreflects post prandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Research and Clinical Practice 2009; 84: 51-57.

McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, GautilleT, et al. U.S. trail of the GlycoMark assay: Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 2004; 27: 1859-1865.

Stickle D, Turk J. A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. American Journal of Physiology 1997; 273: E821–E830.

Onorato JM, Langish RA, Shipkova PA, Sanders M, Wang J, Kwagh J, et al. A novel method for the determination of 1,5-anhydroglucitol, a glycemic marker, in human urine utilizing hydrophilic interaction liquid chromatography/ MS3. Journal of Chromatography B 2008; 873: 144-150.

Yamanouchi T, Akanuma H, Nakamura T, Akaoka I, and Akanuma Y. Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients. Diabetologia 1988; 31: 41-45.

Wright LA, Hirsch IB. The challenge of the use of glycemic biomarkers in diabetes: Reflecting on hemoglobin A1C, 1,5-anhydroglucitol, and the glycated proteins fructosamine and glycated albumin. Diabetes Spectrum 2012; 25: 141-148.

Stettler C, Stahl M, Allemann S, Diem P, Scmidlin K, Zwahlen M, et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008; 31: 1534-1535.

Mehta SN, Schwartz N, Wood JR, Svoren BM, Laffel LM. Evolution of 1,5-anhydroglucitol hemoglobin A1c, and glucose levels in youth and young adults with type 2 diabetes and healthy controls. Pediatric Diabetes 2011; 13: 278-284.

Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, et al. 1,5-anhydro-glucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29: 1214-1219.

Baker JR, O'Connor JP, Metcalf PA, Lawson MR, Johnson RN. Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus. BMJ 1983; 287: 863-867.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 2010; 87: 4- 14.

The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.

Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in pre-diabetes and prehypertension : new findings and their research and clinical implications. Diabetes Care 2007; 30:2708–2715.

Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program. Diabetes Medicine 2007; 24:137–144.

Sumner CJ, Sheth S, Griffin JW , Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003; 60:108–111.

Herman WH. Diabetes epidemiology: guiding clinical and public health practice: the Kelly West Award Lecture, 2006. Diabetes Care 2007; 30:1912–1919.

Barr ELM, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose and impaired glucose tolerance. The Australian Diabetes 2007; 116: 1–7.

Wang Y, Zhang YL, Wang YP, Lei CH, Sun ZL.A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China. Diabetes / Metabolism Research and Reviews 2012; 28: 357-362.

Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow up. Diabetologia 1996; 39: 1577 –1583.

Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000; 23: 45 –50.

Home P. The challenge of poorly controlled diabetes mellitus. Diabetes Metabolism 2003; 29: 101-109.

Sarah W, Gojka R, Anders G, Richard S, Hilary K. Global prevalence of diabetes. Diabetes care 2004; 27: 1047-1053.

Gopinath B, Srisaiprasad M, Jayarama N, Prabhakara K. Study of factors associated with poor glycemic control in type -2 diabetic patients. Global Journal of Medicine and Public Health. 2013; 2: 1-5.

Taha JY, Ajlan SK, Abdul-Salam M. Haemoglobinopathies and glycated haemoglobin: Influence in non-diabetic and diabetic patients. Journal of the Bahrain Medical Society 2005; 17 : 111 - 114.

Al-Naama LM, Ajlan SK, Mahmood MS. Evaluation of lipid and lipoprotein profile in patients with insulin dependent diabetes mellitus. Journal of the Bahrain Medical Society. 2009; 21 : 298 – 301.

Al-Naama LM, Ajlan SK, Mahmood MS. Evaluation of Lipid and Lipoprotein Profile in Patients with Type 2 Diabetes. The Medical Journal of Basrah University 2010; 27: 27-32.

Al-Naama LM, Ajlan SK, Mahmood MS. Glycaemic control in diabetes mellitus. Thi-Qar Med J 2011; 5: 25-29.

Mansour AA. Type II diabetes mellitus: presentations, complications and treatment. The Medical Journal of Basrah University 2002, 20: 41-48.

Ajlan SK, Abdulkader AA, Mijbil AY , The impact of metabolic syndrome in type 2 diabetic patients. The Medical journal of Basrah University 2012; 30: 85-90.

Herman WH, Dungan KM, Wolffenbuttel BHR, Buse JB, Fahrbach JL, Jiang H, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2009: 94: 1689-1694.

Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, Klyne R. Evaluation of serum 1,5-anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 2010; 33: 252-257.

Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 1996; 347:1514–1518.

Lu CC, Lam HC, Chu CH, Chaung MJ, Wang MC, Lee JK. 1,5-anhydroglucitol levels in type 2 diabetic and non-diabetic subjects in Southern Taiwan. Arquivos Brasileiros de Endocrinologia & Metabologia 2003; 47: 711 – 715.

Moses AC, Raskin P, Khutoryansky N. Does Serum 1,5–anhydroglucitol establish a relationship between improvement in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Diabetes Medicine 2008; 25:200-205.

Pramodkumar TA, Jayashri R, Gokulakrishnan K, Velmurugan K, Pradeepa R, Anjana RM, et al. Relationship of glycemic control markers, 1,5-anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance. Journal of Endocrinology and Metabolism 2016; 20: 690-695.

Suzuki SH, Koga M. Glycemic control indicators in patients with neonatal diabetes mellitus. World Journal of Diabetes 2014; 5: 198-208.

Wang Y, Yuan Y, Zhang Y, Lei C, Zhou Y, He J, et al. Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes. Acta Diabetologica 2017; 54: 425-431.

Ying L, He X, Ma X, Shen Y, Su H, Peng J, et al. Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population. Scientific Reports 2017; 7: 1-8.

Halama A, Kulinski M, Abdul Kader S, Satheesh NJ, Abou-Samra A, Suhre K, et al. Measurement of 1,5-anhydroglucitol in blood and saliva: from non- targeted metabolomics to biochemical assay. Journal of Translational Medicine. 2016; 14: 140-149.

Koga M. 1,5-anhydroglucitol and glycated albumin in glycemia. Advance Clinical Chemistry. 2014; 64 : 269-301.

Sun J, Dou JT, Wang XL, Yang GQ, Lu ZH, Zheng H. Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chinese Medical Journal 2011; 124: 3641-3645.

Kim WJ, Park CY. 1,5-anhydroglucitol in diabetes mellitus. Endocrine 2013; 43: 33-40.

Sato A. [Indicators of glycemic control-hemoglobin A1c (HbA1c), glycated albumin (GA), and 1,5-anhydroglucitol (1,5-AG)]. Ransho Byori (The Japanese Journal of Clinical Pathology) 2014; 62: 45-52.

Kim MJ, Jung HS, Hwang-Bo Y, Cho SW, Jang HC, Kim SY, et al. Evaluation of 1,5 anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetologia. 2013; 50: 505-510.

Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson DM, et al. The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. National Institute of Health Public Access 2011; 12: 690–695.

Kinnaird KE, Sauerwein TJ. Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. Endocrinology Practice 2010; 16: 167-170.

Januszewski AS, Karschimkus C, Davis KE, O'Neal D, Ward G, Jenkins AJ. Plasma 1,5-anhydroglucitol levels, a measure of short- term glycemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Research and Clinical Practice. 2012; 95: 17-19.